NASDAQ:ATOS Atossa Therapeutics (ATOS) Stock Forecast, Price & News $0.83 +0.04 (+5.06%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$0.78▼$0.8450-Day Range$0.74▼$1.2052-Week Range$0.50▼$1.39Volume553,452 shsAverage Volume612,960 shsMarket Capitalization$104.40 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Atossa Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside562.7% Upside$5.50 Price TargetShort InterestBearish6.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-1.05Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.27) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 starsMedical Sector858th out of 966 stocksPharmaceutical Preparations Industry411th out of 449 stocks 3.5 Analyst's Opinion Consensus RatingAtossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Atossa Therapeutics has a forecasted upside of 562.7% from its current price of $0.83.Amount of Analyst CoverageAtossa Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.52% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Atossa Therapeutics has recently decreased by 1.80%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Therapeutics does not currently pay a dividend.Dividend GrowthAtossa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATOS. Previous Next 1.1 News and Social Media Coverage News SentimentAtossa Therapeutics has a news sentiment score of -1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atossa Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows6 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Atossa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.27) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Therapeutics is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Therapeutics is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Atossa Therapeutics (NASDAQ:ATOS) StockAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Read More ATOS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATOS Stock News HeadlinesSeptember 18, 2023 | finance.yahoo.comAtossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023September 18, 2023 | finance.yahoo.comApproximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And TreatmentSeptember 23, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 8, 2023 | msn.comCantor Fitzgerald Initiates Coverage of Atossa Therapeutics (ATOS) with Overweight RecommendationSeptember 8, 2023 | msn.comAtossa stock jumps 16% in wake of Cantor overweight ratingSeptember 8, 2023 | markets.businessinsider.comBreast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: AnalystAugust 31, 2023 | msn.comAtossa Therapeutics: Betting Big On Transforming Old Breast Cancer CareAugust 31, 2023 | msn.comAtossa Therapeutics (ATOS) Price Target Increased by 13.51% to 5.36September 23, 2023 | Legacy Research (Ad)Reverse ‘money machines’ popping up across AmericaIf you’ve been to a concert venue, stadium, or airport, you’ve almost certainly walked by one without knowing. The experts are calling it a 'Reverse ATM' Why are these machines suddenly appearing out of nowhere? And what does it mean for your money?August 23, 2023 | proactiveinvestors.comAtossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral EndoxifenAugust 23, 2023 | finance.yahoo.comAtossa Therapeutics backing Endoxifen in the fight against breast cancerAugust 23, 2023 | proactiveinvestors.comAtossa Therapeutics backing Endoxifen in the fight against...Atossa Therapeutics backing Endoxifen in the fight against breast...August 15, 2023 | finance.yahoo.comQ2 2023 Atossa Therapeutics Inc Earnings CallAugust 14, 2023 | finance.yahoo.comAtossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 20, 2023 | msn.comAtossa gains as Canada greenlights breast cancer trialJuly 20, 2023 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in CanadaJuly 20, 2023 | proactiveinvestors.comAtossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in CanadaJuly 14, 2023 | seekingalpha.comAtossa Therapeutics regains compliance with Nasdaq's minimum bid price ruleJuly 11, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Atossa Therapeutics (ATOS)July 11, 2023 | proactiveinvestors.comMaxim upbeat on Atossa Therapeutics after recent updatesJuly 10, 2023 | finanznachrichten.deAtossa Therapeutics, Inc.: Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical TrialJuly 10, 2023 | proactiveinvestors.comAtossa Therapeutics provides update on Phase 2 breast density trial enrollmentJuly 8, 2023 | proactiveinvestors.comAtossa Therapeutics strikes sponsored research deal with Weill Cornell Medicine for triple negative breast cancerJuly 6, 2023 | finance.yahoo.comAtossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast CancerJune 29, 2023 | proactiveinvestors.comAtossa hits 30% enrollment for (Z)-Endoxifen arm of ongoing I-SPY 2 clinical trialJune 28, 2023 | msn.comAtossa jumps 17% after update on mid-stage trial for breast cancer drugJune 28, 2023 | finance.yahoo.comAtossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical TrialSee More Headlines Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATOS Company Calendar Last Earnings8/14/2023Today9/22/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATOS CUSIPN/A CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees11Year Founded2009Price Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$6.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+562.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.97% Return on Assets-24.07% Debt Debt-to-Equity RatioN/A Current Ratio30.48 Quick Ratio30.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book0.89Miscellaneous Outstanding Shares125,790,000Free Float115,974,000Market Cap$104.41 million OptionableNot Optionable Beta1.28 Social Links 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Steven C. Quay FCAP (Age 72)M.D., Ph.D., Chairman, CEO & Pres Comp: $1.14MMr. Gregory L. Weaver CPA (Age 67)M.B.A., CFO & Director Comp: $80kMs. Heather ReesVP of Fin. & AccountingMs. Delly Behen P.H.R.VP of Admin. & HRMr. Eric Van ZantenVP of Investor & PRDr. Richard Graydon M.D.Ph.D., Interim Chief Medical OfficerMore ExecutivesKey CompetitorsSpruce BiosciencesNASDAQ:SPRBNGM BiopharmaceuticalsNASDAQ:NGMMilestone PharmaceuticalsNASDAQ:MISTLumiraDxNASDAQ:LMDXAnnovis BioNYSE:ANVSView All CompetitorsInstitutional OwnershipXTX Topco LtdBought 39,383 shares on 8/15/2023Ownership: 0.031%Citadel Advisors LLCBought 2,600 shares on 8/15/2023Ownership: 0.000%State Street CorpSold 44,724 shares on 8/14/2023Ownership: 0.345%Two Sigma Securities LLCBought 25,178 shares on 8/14/2023Ownership: 0.020%Geode Capital Management LLCSold 98,273 shares on 8/11/2023Ownership: 0.879%View All Institutional Transactions ATOS Stock - Frequently Asked Questions Should I buy or sell Atossa Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATOS shares. View ATOS analyst ratings or view top-rated stocks. What is Atossa Therapeutics' stock price forecast for 2023? 1 brokers have issued 1-year price objectives for Atossa Therapeutics' shares. Their ATOS share price forecasts range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 562.7% from the stock's current price. View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts. How have ATOS shares performed in 2023? Atossa Therapeutics' stock was trading at $0.5285 on January 1st, 2023. Since then, ATOS stock has increased by 57.0% and is now trading at $0.83. View the best growth stocks for 2023 here. When is Atossa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our ATOS earnings forecast. How were Atossa Therapeutics' earnings last quarter? Atossa Therapeutics, Inc. (NASDAQ:ATOS) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). When did Atossa Therapeutics' stock split? Atossa Therapeutics shares reverse split before market open on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO? 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend. What other stocks do shareholders of Atossa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK). What is Atossa Therapeutics' stock symbol? Atossa Therapeutics trades on the NASDAQ under the ticker symbol "ATOS." Who are Atossa Therapeutics' major shareholders? Atossa Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.29%), Geode Capital Management LLC (0.88%), Renaissance Technologies LLC (0.85%), State Street Corp (0.34%), Bank of New York Mellon Corp (0.09%) and Virtu Financial LLC (0.07%). View institutional ownership trends. How do I buy shares of Atossa Therapeutics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Atossa Therapeutics' stock price today? One share of ATOS stock can currently be purchased for approximately $0.83. How much money does Atossa Therapeutics make? Atossa Therapeutics (NASDAQ:ATOS) has a market capitalization of $104.41 million. The company earns $-26,960,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. How can I contact Atossa Therapeutics? Atossa Therapeutics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The official website for the company is atossatherapeutics.com. The company can be reached via phone at (206) 588-0256, via email at scottg@coreir.com, or via fax at 206-430-1288. This page (NASDAQ:ATOS) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.